AFFiRiS AG successfully raises €10m equity financing• € 10m additional capital raised
• Strengthened management team, Günther Staffler appointed as Chief Technology Officer
• Noel Barrett appointed as additional member of the supervisory board
AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016.
In an extraordinary shareholders' meeting on 29 April 2016 the shareholders of the company have agreed to a capital increase of € 10m. The new shares have equally been subscribed by the two major investors of the company, Santo Holding – the family office of the Strüngmann family – , the MIG Funds advised by MIG Verwaltungs AG and new investor FCPG Affi GmbH. In the ordinary shareholders' meeting on 15 June 2016 the shareholders also elected Noel Barrett as additional member of the Supervisory Board. He replaces Dr. Frank Mattner whose tenure as supervisory board member has ended on 31 December 2015.
Noel Barrett has more than 30 years’ experience in the vaccines and biotechnology industry with management responsibilities covering the complete development process required to bring vaccine products to the market. In his last position at Baxter Healthcare, Noel Barrett was Vice President, Global R&D Vaccines and has successfully overseen the development of numerous vaccine candidates through preclinical and clinical development.
Michael Motschmann, Chairman of the Supervisory Board of AFFiRiS commented: "We are excited to welcome Noel Barrett to the Supervisory Board of AFFiRiS. His product development expertise will be tremendously valuable as the company focuses on advancing its projects in clinical development."
The company has decided to adapt its management structure to focus on development, both preclinical and clinical of its projects. All preclinical development will be led by Günther Staffler (48) whom the Supervisory Board has appointed as Chief Technology Officer and member of the executive board of AFFiRiS. Günther Staffler has previously been responsible as Head of Immunology for the preclinical development of its vaccine candidates AT04A and AT06A in Hypercholesterolemia and Atherosclerosis prevention which are currently being tested in Phase 1 clinical development. The company also announces the departure of Achim Schneeberger, previously Chief Medical Officer and Arne von Bonin, Chief Scientific Officer.
AFFIRIS commenced Phase 1 clinical development of its Hypercholesterolemia and Atherosclerosis prevention vaccine candidates AT04A and AT06A and expects data from this study in Q1 2017. AT04A and AT06A are vaccine candidates from the next generation AFFITOME® technology and target PCSK9, an enzyme which plays a role in the lipid metabolism of the liver. If PCSK9 is blocked, more LDL receptors will be present on the surface of the liver and will remove more LDL cholesterol from the blood. Therefore, blocking PCSK9 can lower blood cholesterol levels.
About AFFiRiS AG:
On the basis of its proprietary patented AFFITOME®-technolgy, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of 3 drug candidates against Parkinson’s, MSA and Hypercholesterolemia. Further vaccine candidates against diabetes, allergies, asthma as well as Huntington's disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 130m to date, half of which comes from license income and government grants. AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.
Contact AFFiRiS AG:
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 - 300
PR&D – Public Relations for Research & Education
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AFFiRiS AG successfully raises €10m equity financing here
News-ID: 345631 • Views: 1073
More Releases from AFFiRiS AG
Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG
Vaccine Specialist AFFiRiS AG successfully completes Financing Round • € 10m additional capital raised • Supervisory Board appoints Oliver Siegel as Chief Executive Officer • Prof. Dr. Christoph Huber elected to Supervisory Board AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the
New board member joins AFFiRiS AG
Vienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will take over responsibility for Business Development, Finance and Administration. The appointment of the international experienced transaction expert extends the know-how of the board with a focus on partnering and business operations. Oliver Siegel will expend his experience gained at leading international investment banks to focus
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a
Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing Vienna, November 18, 2009: AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of
More Releases for Noel
Know in Detail about Silicon Wafer Reclaim Market By Top Players like- Noel Tech …
Details Overview Of Silicon Wafer Reclaim Market Insights 2022 This section discusses about various aspects of Silicon Wafer Reclaim sector, including its size, trends, revenue forecasts and Latest Update: This has brought along several changes this report also covers the impact of Current COVID-19 situation. Sample Request Now The Silicon Wafer Reclaim Market Research literature also presents sections exclusive to assessing and concluding the revenue prospects for each market sector. The Silicon Wafer
Silicon Wafer Reclaim Market 2021-2027 with Top Prominent Players like - Nano Si …
The report studies the Global Silicon Wafer Reclaim Market with many aspects of the industry like the market size, market status, market trends, and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. The report offers valuable insight into the Silicon Wafer Reclaim Market progress and approaches related to the market with an analysis of each region. The report goes
Global Silicon Wafer Reclaim Market 2018 - Nano Silicon, Advantec, KST World Cor …
Eminent Market Reports, recently published a detailed market research study focused on the “Silicon Wafer Reclaim Market” across the global, regional and country level. The report provides 360° analysis of “Silicon Wafer Reclaim Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Silicon
Global Silicon Wafer Reclaim Market 2018 - Nano Silicon, Advantec, KST World Cor …
Apex Market Reports, recently published a detailed market research study focused on the “Silicon Wafer Reclaim Market” across the global, regional and country level. The report provides 360° analysis of “Silicon Wafer Reclaim Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Silicon
Pook & Pook and Noel Barrett to Host Sept. 15 American & European Antique Toy Au …
DOWNINGTOWN, PA – Premier Pennsylvania auction house Pook & Pook and veteran toy auctioneer Noel Barrett will jointly host a treasure-filled auction of American and European antique tin toys, trains, dollhouses and vintage objects of interest on Friday, Sept. 15. The 500-lot sale will take place at the historic Pook & Pook gallery in Downingtown, Pa. (suburban Philadelphia), with all forms of bidding available, including absentee and live via the
Anna Ivlieva & Jean-Noel Chazelle at du Film de Cannes Festival 2012
Cannes, France - Jean-Noel Chazelle is a French ARealist artist who creates large scale panel installations, paintings and design. Chazelle is considered to be one of the major influences in contemporary art scene and one of the most colorful and entertaining painters in the world. In May of 2012 Chazelle was invited to showcase his art work at a private residence of a famous European entrepreneur and life style designer Richard